Related Experiment Video

Updated: Oct 12, 2025

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.6K

Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials

Takahito Kawano1, Junichi Inokuchi2, Masatoshi Eto1,2

  • 1Center for Advanced Medical Innovation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

Pharmaceutics
|November 27, 2021
PubMed

Insights

Protein kinase C (PKC) activators and inhibitors are crucial for understanding cell signaling and treating diseases like cancer. However, PKC inhibitors show limited success in cancer therapy, highlighting the need for nuanced strategies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Protein kinase C (PKC) is a family of serine/threonine kinases involved in various cellular processes.
  • PKC isozymes are classified into three subfamilies: conventional (cPKCs), novel (nPKCs), and atypical (aPKCs).
  • PKC signaling pathways are implicated in diseases including cancer, neurological disorders, cardiovascular conditions, and infections.

Purpose of the Study:

  • To review the activators and inhibitors of Protein Kinase C (PKC).
  • To discuss the applications of PKC modulators in clinical trials.
  • To highlight the limitations of targeting PKC alone in cancer therapy.

Main Methods:

  • Literature review of scientific articles and clinical trial data.
  • Analysis of studies focusing on PKC activators and inhibitors.
  • Examination of therapeutic strategies involving PKC modulators.

Main Results:

  • PKC activators and inhibitors are valuable tools for elucidating intracellular signaling.
  • Clinical trials, particularly for cancer, have shown limitations in the efficacy of PKC inhibitors as monotherapy.
  • The review synthesizes current knowledge on PKC modulators and their clinical relevance.

Conclusions:

  • PKC modulators play a significant role in both basic research and therapeutic development.
  • Targeting PKC alone in cancer treatment presents challenges, suggesting combination therapies may be more effective.
  • Further research into PKC pathways and modulator applications is warranted for diverse diseases.
Keywords:
activatorcancerclinical trialinhibitorprotein kinase Csignaling pathway

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.9K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.7K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
13.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.1K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.4K